IDACO Consulting Limited
IDACO Consulting Limited
IDACO Consulting Limited is a solution-oriented consultancy with a specific focus on supporting companies in the Pharmaceutical, Biotechnology, Medical Device, Life Science and Healthcare sectors.
The IDACO Team bring together pre-clinical and clinical expertise, along with an extensive network of academic, outsourcing and commercial contacts, to support the development and commercialisation of bio-pharmaceutical products and medical devices.
IDACO Consulting also has the capabilities to undertake projects involving healthcare including the optimisation of healthcare services.
Ian Cox
Director
ImmuPharma plc
ImmuPharma PLC is a pharmaceutical development company listed since 2006 on AIM of the London Stock Exchange (LSE:IMM). The company is focusing on developing novel medicines for specialist indications with serious unmet need. ImmuPharma has five drug candidates in development, two platform technologies and over 70 patents. Forigerimod (P140 or Lupuzor™) is the company’s most advanced drug candidate for autoimmune diseases and is an immunomodulator, not an immunosuppressant. Lupuzor ™ received "Fast Track" designation from the US FDA and has recently completed a Phase III trial.
Forigerimod is a first-in-class peptide drug modulating autophagy.
ImmuPharma is based in London, U.K. and has three subsidiaries in France and one in Switzerland.
Dimitri Dimitriou
Chief Executive Officer
Intract Pharma
- Licensing and product Development
- Spin out from UCL School of Pharmacy based on 20+ years research from laboratory of Prof. Abdul Basit
- Experts in oral drug delivery, range of licensable technologies for targeted delivery in GI tract
- Unique GI models that provide expert analysis of formulation behaviour under physiologically appropriate conditions
